Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 12Carcinoma, Hepatocellular 11Carcinoma, Non-Small-Cell Lung 9Nasopharyngeal Carcinoma 8Esophageal Squamous Cell Carcinoma 8Stomach Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Breast Neoplasms 5Uterine Cervical Neoplasms 4Small Cell Lung Carcinoma 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Sarcoma 3Neoplasm Metastasis 3Lung Neoplasms 3Hypopharyngeal Neoplasms 3Cholangiocarcinoma 3Solid Tumor 2Recurrence 2Lymphoma 2Laryngeal Neoplasms 2Head and Neck Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Upper Tract Urinary Carcinoma 1Thyroid Neoplasms 1Thymic epithelial tumor 1

Interventions

spartalizumab 2pegaspargase 2Methylprednisolone 2Etoposide 2Dexamethasone 2toripalimab 1ruxolitinib 1Valproic Acid 1Valganciclovir 1Rituximab 1Liquid Biopsy 1Lenalidomide 1Gemcitabine 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Epstein-Barr Virus Infections × toripalimab × Clear all
NCT04690036 2021-06-29

PD-1 Antibody for Reactive EBV After BMT

Beijing Friendship Hospital

Phase EARLY_PHASE1 Unknown
20 enrolled

Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡